SGMT Sagimet Biosciences Inc: Rasio rega marang prakiraan pendapatan

Sagimet Biosciences - logo grafis emiten SGMT

High trial uncertainty and a revenue deficit create significant risks for Sagimet Biosciences (SGMT). The forward P/S trend visualizes these expectations, where the value 50.90 serves as the baseline for the current valuation. The company is diversifying its portfolio by developing treatments for acne and liver pathologies, while R&D cost optimization is achieved by outsourcing molecule testing to third-party contractors.

Sagimet Biosciences Inc. - Rasio kapitalisasi marang dodolan sing dikarepake SGMT (periode 26.03.2024 - 16.11.2024)

Ringkesan rincian data analitis sagimet.com (SGMT)

- rega pasar lan target rega analis:
Analisis komprehensif perusahaan:Sagimet Biosciences, Inc. SGMT
Produk asli Sagimet Biosciences

Driven by breakthrough clinical successes in liver therapy, Sagimet Biosciences (SGMT) is perceived by the market as a future industry leader with significant reputational capital. By analyzing the trajectory of the forward P/S ratio, investors can determine the company's current valuation relative to expected revenue, allowing for a real-time assessment of market confidence in the business's scaling pace without waiting for quarterly reports.

Pesaing Sagimet Biosciences

Rasio rega marang prakiraan pendapatan ascendispharma.com ASND|Madrigal Corp (MDGL) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|CORT - Rasio rega marang prakiraan pendapatan|RYTM: Rasio rega marang prakiraan pendapatan|AKRO: Multiplikator Forward P/S|MTSR - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan MoonLake Corp|Crinetics Corp (CRNX) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan newamsterdampharma.com (NAMS)|Multiplikator forward rega marang pendapatan soleno.life SLNO|Multiplikator Forward P/S FOLD (amicusrx.com)|Rasio kapitalisasi marang dodolan sing dikarepake 89bio (ETNB)|Agios - Multiplikator Forward P/S|Structure Corp - Rasio rega marang pendapatan sing dikarepake|mimedx.com (MDXG) - Rasio rega marang prakiraan pendapatan|Rega mangsa ngarep marang pendapatan RZLT (rezolutebio.com)|LXRX (Lexicon Pharmaceuticals Inc) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan MBX|Rasio rega marang prakiraan pendapatan Altimmune Pharma (ALT)|Rasio rega marang prakiraan pendapatan AARD (Aardvark Therapeutics Corp)|Multiplikator Forward P/S BIOA (BioAge Labs)|Multiplikator Forward P/S Biomea Fusion BMEA|QNCX: Multiplikator forward rega marang pendapatan|GUTS: Rasio rega marang prakiraan pendapatan|vTv Therapeutics Inc (VTVT) - Rasio rega marang prakiraan pendapatan|ATPC: Rasio rega marang pendapatan sing dikarepake|PLUR (pluri-biotech.com) - Multiplikator Forward P/S|SYBX: Rega forward marang dodolan|Multiplikator Forward P/S LPCN|Rasio kapitalisasi marang dodolan sing dikarepake Matinas BioPharma Holdings, Inc.|Rasio rega marang prakiraan pendapatan Spruce Biosciences Inc. SPRB|GLTO - Multiplikator forward rega marang pendapatan|CTCX - Rasio rega marang prakiraan pendapatan|LUMO - Multiplikator Forward P/S|ONVO: Multiplikator Forward P/S|RDUS (Radius Recycling) - Rasio rega marang prakiraan pendapatan